Clinical trials: Colorectal Carcinoma (CRC)
Colorectal Cancer Metastatic
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Primary Objective: To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).
- Trial name
- NCT01882868
- Testing
- Aflibercept, Levofolinate, Irinotecan
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
- Trial name
- NCT05281276
- Testing
- chidamide, celecoxib
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Colorectal Cancer, Rectal Cancer
SafeHeal Colovac Colorectal Anastomosis Protection Device Evaluation (SAFE-2) Pivotal Study
A randomized trial to assess the safety and effectiveness of the Colovac in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer.
- Conditions
- Colorectal Cancer, Rectal Cancer, Rectal Tumor, Rectal/Anal
- Trial name
- SAFE-2 (NCT05010850)
- Testing
- Colovac, Stoma Creation
- Where
- 16 sites in United States, Belgium and 1 more
- Volunteers
- 18 people
- Sponsor
- SafeHeal Inc
Colorectal Cancer
Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab
Prometheus's Onco dX assay platform provides technological breakthrough for immunoassay by obtaining a level of sensitivity down to single tumor cells without compromising specificity.
- Trial name
- NCT02029326
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Rectal Cancer, Adenocarcinoma, Neoadjuvant Chemoradiation
Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer
In this study, we aim to investigate the value of circulating tumor DNA (ctDNA) analysis in the diagnosis, treatment, and surveillance of patients with surgically resectable colorectal cancer, by performing serial analysis of…
- Trial name
- NCT03038217
- Testing
- Capecitabine +/- Oxaliplatin, local resection, radical resection
- Volunteers
- 300 people
- Sponsor
- Peking Union Medical College Hospital
Metastatic Colorectal Cancer (CRC)
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
- Trial name
- NCT07309289
- Testing
- NALIRIFOX plus targeted therapy, FOLFOX plus targeted therapy
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
RAS mutations are found in nearly half of colorectal cancer patients. However, except for G12C mutation, no driven gene targeted drug can be used.
- Trial name
- NCT05842525
- Testing
- intensive treatment, Maintenance treatment
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
The combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with KRAS wild type colorectal cancer.
- Trial name
- NCT00954876
- Testing
- capecitabine and cetuximab
- Where
- United States
- Sponsor
- Translational Genomics Research Institute
Metastatic Colorectal Cancer
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum…
- Trial name
- NCT01966289
- Testing
- CY, GVAX, SGI-110
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Breast Cancer, Advanced Colorectal Cancer
Rehabilitation for People With Advanced Cancer
The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.
- Conditions
- Advanced Breast Cancer, Advanced Colorectal Cancer, Cancer Rehabilitation
- Trial name
- NCT05424068
- Testing
- In-person rehabilitaiton group, Virtual rehabilitation group
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Objectives: 1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as…
- Trial name
- NCT00354978
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer Metastatic, Mismatch Repair Deficiency
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer Metastatic, Mismatch Repair Deficiency, Microsatellite Instability High
- Trial name
- NCT04482608
- Where
- China
- Volunteers
- 671 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Colorectal Cancer
Study of Imprime PGG® in Combination With Cetuximab in Subjects With Recurrent or Progressive KRAS Wild Type Colorectal Cancer
Study BT-CL-PGG-CRC1031 is a Phase 3, open-label, randomized, multi-center study. Qualified subjects, who have KRAS wild type (WT) colorectal cancer will be randomized in a 2:1 ratio to treatment with either Imprime PGG and…
- Trial name
- PRIMUS (NCT01309126)
- Testing
- Imprime PGG + cetuximab, Cetuximab
- Where
- 53 sites in United States, France and 2 more
- Volunteers
- 217 people
- Sponsor
- HiberCell, Inc.
Cancer of Colon
Psoas Density in Colorectal Cancer
Colorectal cancer (CRC) is the 3rd most common cancer worldwide. In the UK, CRC is the 4th most common cancer accounting for 12% of cancers diagnosed each year with approximately 41,300 new cases diagnosed in 2014.
- Trial name
- NCT04198025
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- University of Nottingham
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Advanced Solid Tumor, Colorectal Cancer
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-3-600 in patients with advanced cancer
- Trial name
- NCT05948826
- Testing
- TORL-3-600
- Where
- 9 sites in United States, Canada
- Volunteers
- 70 people
- Sponsor
- TORL Biotherapeutics, LLC
EGFR-positive Colorectal Cancer
EGFR CART Cells for Patients With Metastatic Colorectal Cancer
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
- Trial name
- NCT03152435
- Testing
- EGFR CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
BRAF V600E-mutant Metastatic Colorectal Cancer
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer
This trial aims to elucidate the immune landscape and genetic basis of BRAF-mutant colorectal cancer (CRC) in Chinese patients by analyzing tumor tissue and peripheral blood.
- Trial name
- NCT07007689
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer, BRAF V600 Mutation
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Previous studies have shown that BRAFV600E mutant mCRC patients have a shorter survival time than BRAF wild type mCRC patients. For Chinese patients, however, it remains unclear about the BRAF gene mutation rate, diagnosis…
- Trial name
- NCT06749015
- Testing
- Non interventional study
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.